Vanda Financial Statements From 2010 to 2024

VNDA Stock  USD 4.56  0.07  1.51%   
Vanda Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Vanda Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Vanda Pharmaceuticals financial statements helps investors assess Vanda Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Vanda Pharmaceuticals' valuation are summarized below:
Gross Profit
230.1 M
Profit Margin
0.013
Market Capitalization
266.4 M
Enterprise Value Revenue
0.5857
Revenue
192.6 M
We have found one hundred twenty available fundamental trend indicators for Vanda Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vanda Pharmaceuticals current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 385.7 M, whereas Enterprise Value is forecasted to decline to about 109.9 M.

Vanda Pharmaceuticals Total Revenue

137.02 Million

Check Vanda Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vanda main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 M, Interest Expense of 6 M or Total Revenue of 137 M, as well as many exotic indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0 or PTB Ratio of 0.42. Vanda financial statements analysis is a perfect complement when working with Vanda Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Vanda Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Vanda Pharmaceuticals Technical models . Check out the analysis of Vanda Pharmaceuticals Correlation against competitors.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.

Vanda Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets680.9 M648.4 M345.8 M
Slightly volatile
Short and Long Term Debt TotalM9.4 M11 M
Pretty Stable
Other Current Liabilities79.5 M75.7 M41.2 M
Slightly volatile
Total Current Liabilities44.2 M87.7 M50.3 M
Slightly volatile
Total Stockholder Equity572.2 M544.9 M263.3 M
Slightly volatile
Other Liabilities5.8 M6.1 M24.8 M
Slightly volatile
Property Plant And Equipment Net5.4 M9.1 M6.4 M
Slightly volatile
Accounts Payable6.8 M9.6 M7.9 M
Slightly volatile
Cash72.3 M135.8 M67.1 M
Slightly volatile
Non Current Assets Total226.3 M215.5 M77 M
Slightly volatile
Non Currrent Assets Other10 M9.5 M4.4 M
Slightly volatile
Other Assets103.1 M98.2 M37.8 M
Slightly volatile
Cash And Short Term Investments208.8 M388.3 M227.2 M
Slightly volatile
Common Stock Total Equity39.5 K65.5 K42.7 K
Slightly volatile
Common Stock Shares Outstanding48.2 M57.6 M73.8 M
Slightly volatile
Liabilities And Stockholders Equity680.9 M648.4 M345.8 M
Slightly volatile
Non Current Liabilities Total29.4 M15.8 M29.9 M
Slightly volatile
Other Current Assets6.8 M9.2 MM
Slightly volatile
Other Stockholder Equity445.4 M700.3 M481.8 M
Slightly volatile
Total Liabilities84.6 M103.5 M80.9 M
Pretty Stable
Property Plant And Equipment Gross21.3 M20.3 M7.5 M
Slightly volatile
Total Current Assets230.7 M432.9 M253.8 M
Slightly volatile
Short Term Debt2.5 M2.4 M8.3 M
Pretty Stable
Common Stock40.7 K58 K42.3 K
Slightly volatile
Property Plant Equipment3.5 MM3.9 M
Slightly volatile
Short Term Investments151.7 M252.4 M161.8 M
Slightly volatile
Net Receivables35.9 M34.2 M18.9 M
Slightly volatile
Intangible Assets127.4 M121.4 M33.8 M
Slightly volatile
Net Tangible Assets614.2 M584.9 M255.3 M
Slightly volatile
Capital Surpluse578 M789.2 M520 M
Slightly volatile
Long Term Investments15.2 M17.1 M18.6 M
Slightly volatile
Long Term Debt Total20 M22.5 M24.5 M
Slightly volatile
Non Current Liabilities Other9.9 M8.8 M7.3 M
Slightly volatile
Net Invested Capital447.6 M544.9 M281 M
Slightly volatile
Short and Long Term Debt21.6 M24.3 M26.5 M
Slightly volatile
Net Working Capital339.5 M345.2 M213.1 M
Slightly volatile
Capital Stock60.9 K58 K53.9 K
Slightly volatile
Capital Lease Obligations9.8 M9.4 M13.5 M
Slightly volatile

Vanda Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.8 MM3.2 M
Very volatile
Total Revenue137 M192.6 M139.4 M
Slightly volatile
Gross Profit123.7 M192.6 M126.1 M
Slightly volatile
Other Operating Expenses128.7 M206.6 M145.2 M
Slightly volatile
Research Development42.8 M76.8 M43.6 M
Slightly volatile
Cost Of Revenue19.7 M17.6 M21.7 M
Very volatile
Total Operating Expenses118 M206.6 M132.1 M
Slightly volatile
Total Other Income Expense Net21.3 M20.3 M9.5 M
Very volatile
Selling General Administrative75.8 M122.1 M85.1 M
Slightly volatile
Non Operating Income Net Other368.8 K414.9 K451.8 K
Slightly volatile
Reconciled Depreciation2.3 M2.5 M2.9 M
Slightly volatile
Selling And Marketing Expenses475 K500 K3.7 M
Very volatile

Vanda Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow141.8 M135 M65.1 M
Slightly volatile
Depreciation3.3 MM3.9 M
Very volatile
Capital Expenditures363.9 K383 K3.2 M
Very volatile
Total Cash From Financing Activities574.8 K605 K20 M
Pretty Stable
End Period Cash Flow72.4 M135.8 M67.3 M
Slightly volatile
Stock Based Compensation13.3 M14 M418.4 M
Slightly volatile
Sale Purchase Of Stock627.6 K660.6 K17.2 M
Pretty Stable
Exchange Rate Changes25.3 K46 K23.6 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.191.2578.9 K
Slightly volatile
PTB Ratio0.420.444422.4532
Slightly volatile
Days Sales Outstanding57.2964.714455.5501
Pretty Stable
Book Value Per Share9.979.49645.0766
Slightly volatile
Invested Capital0.02730.01730.0326
Slightly volatile
Average Payables1.7 M1.8 M1.6 M
Slightly volatile
Stock Based Compensation To Revenue0.06920.07290.2436
Slightly volatile
PB Ratio0.420.444422.4532
Slightly volatile
EV To Sales0.570.60088.9 K
Slightly volatile
Inventory Turnover12.8712.443613.8979
Slightly volatile
Days Of Inventory On Hand27.8729.3323213
Slightly volatile
Payables Turnover1.681.76743.6772
Slightly volatile
Sales General And Administrative To Revenue1.030.58340.988
Slightly volatile
Average Inventory643.9 K1.1 M1.1 M
Very volatile
Research And Ddevelopement To Revenue0.380.398815.022
Slightly volatile
Cash Per Share3.646.76644.7766
Slightly volatile
Days Payables Outstanding262207277
Slightly volatile
Intangibles To Total Assets0.20.18720.0923
Pretty Stable
Current Ratio7.134.93686.1547
Pretty Stable
Tangible Book Value Per Share7.757.38124.4145
Slightly volatile
Receivables Turnover5.365.640210.1974
Slightly volatile
Graham Number5.623.05666.4972
Slightly volatile
Shareholders Equity Per Share9.979.49645.0766
Slightly volatile
Debt To Equity0.02730.01730.0326
Slightly volatile
Revenue Per Share2.063.35722.7931
Slightly volatile
Interest Debt Per Share0.170.16390.2045
Pretty Stable
Debt To Assets0.02380.01450.0287
Slightly volatile
Operating Cycle89.3494.0467269
Slightly volatile
Price Book Value Ratio0.420.444422.4532
Slightly volatile
Days Of Payables Outstanding262207277
Slightly volatile
Company Equity Multiplier1.131.192.5057
Slightly volatile
Long Term Debt To Capitalization0.02060.01270.0246
Slightly volatile
Total Debt To Capitalization0.02650.0170.0315
Slightly volatile
Debt Equity Ratio0.02730.01730.0326
Slightly volatile
Quick Ratio6.884.81685.9246
Pretty Stable
Net Income Per E B T0.380.39581.0547
Pretty Stable
Cash Ratio1.471.54882.3764
Slightly volatile
Days Of Inventory Outstanding27.8729.3323213
Slightly volatile
Days Of Sales Outstanding57.2964.714455.5501
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.10.97011.0108
Very volatile
Price To Book Ratio0.420.444422.4532
Slightly volatile
Fixed Asset Turnover17.4721.076621.7287
Pretty Stable
Debt Ratio0.02380.01450.0287
Slightly volatile
Price Sales Ratio1.191.2578.9 K
Slightly volatile
Asset Turnover0.290.29710.3943
Slightly volatile
Gross Profit Margin0.690.91230.8603
Pretty Stable
Price Fair Value0.420.444422.4532
Slightly volatile

Vanda Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap385.7 M242.1 M528 M
Slightly volatile
Enterprise Value109.9 M115.7 M450.9 M
Pretty Stable

Vanda Fundamental Market Drivers

Forward Price Earnings30.303
Cash And Short Term Investments388.3 M

Vanda Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vanda Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Vanda Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Vanda Pharmaceuticals investors use historical funamental indicators, such as Vanda Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Vanda Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Vanda Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Vanda Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Vanda Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Vanda Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-5.2 M-5 M
Total Revenue192.6 M137 M
Cost Of Revenue17.6 M19.7 M
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue 0.58  1.03 
Research And Ddevelopement To Revenue 0.40  0.38 
Capex To Revenue(0)(0)
Revenue Per Share 3.36  2.06 
Ebit Per Revenue(0.07)(0.08)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vanda Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vanda Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vanda Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vanda Pharmaceuticals Stock:
Check out the analysis of Vanda Pharmaceuticals Correlation against competitors.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.
Note that the Vanda Pharmaceuticals information on this page should be used as a complementary analysis to other Vanda Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Vanda Stock analysis

When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Is Vanda Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
0.04
Revenue Per Share
3.357
Quarterly Revenue Growth
(0.30)
Return On Assets
(0.01)
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.